Drugs / Nanoliposomal CPT-11
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00734682 | Aug 2008 → Dec 2014 | anaplastic astrocytoma, anaplastic oligodendroglioma, gliosarcoma | University of California, San Francisco | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nanoliposomal CPT-11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00734682 ↗ |
| Route | Intravenous | “Patients with recurrent malignant glioma will receive Nanoliposomal CPT-11 at the time of relapse. The dose will be adjusted according to a phase-1 dose escalation scheme....” NCT00734682 ↗ |